Combretastatin dinitrogen-substituted stilbene analogues as tubulin-binding and vascular-disrupting agents

Journal of Natural Products

Volumn 71, Issue 3, 2008, Pages 313-320

  Siles, Rogelio ^a   Ackley, J Freeland ^a   Hadimani, Mallinath B ^a   Hall, John J ^a   Mugabe, Benon E ^a   Guddneppanavar, Rajsekhar ^a   Monk, Keith A ^a   Chapuis, Jean Charles ^c   Pettit, George R ^c   Chaplin, David J ^d   Edvardsen, Klaus ^b   Trawick, Mary Lynn ^a   Garner, Charles M ^a   Pinney, Kevin G ^a  

^a BAYLOR UNIVERSITY   (United States)

^b LUND UNIVERSITY   (Sweden)

^c ARIZONA STATE UNIVERSITY   (United States)

^d OXiGENE Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2' AMINE 4' METHOXY 5' NITROPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)ETHENE; 2 (2' AMINO 4' METHOXY 5' NITROPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)ETHENE; 2 (2',3' DIAMINE 4' METHOXYPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)ETHENE; 2 (2',3' DIAMINO 4' METHOXYPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)ETHENE; 2 (2',5' DIAMINE 4' METHOXYPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)ETHENE; 2 (2',5' DIAMINO 4' METHOXYPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)ETHENE; 2 (3',5' DIAMINE 4' METHOXYPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)ETHANE LEVO SERINAMIDE; 2 (3',5' DIAMINO 4' METHOXYPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)ETHANE SERINAMIDE; 2 (3',5' DIAMINO 4' METHOXYPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)ETHENE; 2 (4' METHOXY 2',3' DINITROPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)ETHENE; 2 (4' METHOXY 2',5' DINITROPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)ETHENE; 2 (4' METHOXY 3',5' DINITROPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)ETHENE; 2 (5' AMINO 4' METHOXY 2' NITROPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)ETHENE; COMBRETASTATIN; STILBENE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; SCID MOUSE; STRUCTURE ACTIVITY RELATION; TUMOR BLOOD FLOW;

ANIMALS; ANTINEOPLASTIC AGENTS; BIBENZYLS; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; LEUKEMIA P388; MICE; MOLECULAR STRUCTURE; NEOPLASMS; REGIONAL BLOOD FLOW; STILBENES; TUBULIN;

MUS;

EID: 42249093853     PISSN: 01633864     EISSN: None     Source Type: Journal    
DOI: 10.1021/np070377j     Document Type: Article

References (46)

1. Pettit, G. R.; Cragg, G. M.; Herald, D. L.; Schmidt, J. M.; Lohavanijaya, P. Can. J. Chem. 1982, 60, 1374-1376.
2. Pettit, G. R.; Cragg, G. M.; Singh, S. B. J. Nat. Prod. 1987, 50, 386-391.
3. Lin, C. M.; Ho, H. H.; Pettit, G. R.; Hamel, E. Biochemistry 1989, 28, 6984-6991.
4. Pettit, G. R.; Singh, S. B.; Niven, M. L.; Hamel, E.; Schmidt, J. M. J. Nat. Prod. 1987, 50, 119-131.
5. Pettit, G. R.; Rhodes, M. R. Anti-Cancer Drug Des. 1998, 13, 183-191.
6. Pettit, G. R.; Temple, C., Jr.; Narayanan, V. L.; Vanna, R.; Simpson, M. J.; Boyd, M. R.; Rener, G. A.; Bansal, N. Anti-Cancer Drug Des. 1995, 10, 299-309.
7. Pettit, G. R.; Lippert, J. W., III Anti-Cancer Drug Des. 2000, 15, 203-216.
8. Hamel, E.; Lin, C. M. Biochem. Pharmacol. 1983, 32, 3864-3867.
9. Pettit, G. R.; Singh, S. B. Can. J. Chem. 1987, 65, 2390-2396.
10. Dark, G. G.; Hill, S. A.; Prise, V. E.; Tozer, G. M.; Pettit, G. R.; Chaplin, D. J. Cancer Res. 1997, 57, 1829-1834.
11. Iyer, S.; Chaplin, D. J.; Rosenthal, D. S.; Hamid Boulares, A.; Li, L.; Smulson, M. E. Cancer Res. 1998, 58, 4510-4514.
12. Galbraith, S. M.; Chaplin, D. J.; Lee, F.; Stratford, M. R. L.; Locke, R. J.; Vojnovic, B.; Tozer, G. M. Anticancer Res. 2001, 21, 93-102.
13. Young, S.; Chaplin, D. J. Expert Opin. Investig. Drugs 2004, 13, 1171-1182.
14. Kanthou, C.; Tozer, G. M. Blood 2002, 99, 2060-2069.
15. Sheng, Y.; Hua, J.; Pinney, K. G.; Garner, C. M.; Kane, R. R.; Prezioso, J. A.; Chaplin, D. J.; Edvardsen, K. Int. J. Cancer 2004, 111, 604-610.
16. Ohsumi, K.; Nakagawa, R.; Fukuda, Y.; Hatanaka, T.; Morinaga, Y.; Nihei, Y.; Ohishi, K.; Suga, Y.; Akiyama, Y.; Tsuji, T. J. Med. Chem. 1998, 41, 3022-3032.
17. Ohsumi, K.; Hatanaka, T.; Fujita, K.; Nakagawa, R.; Fukuda, Y.; Nihei, Y.; Suga, Y.; Morinaga, Y.; Akiyama, Y.; Tsuji, T. Bioorg. Med. Chem. Lett. 1998, 8, 3153-3158.
18. Hatanaka, T.; Fujita, K.; Ohsumi, K.; Nakagawa, R.; Fukuda, Y.; Nihei, Y.; Suga, Y.; Akiyama, Y.; Tsuji, T. Bioorg. Med. Chem. Lett. 1998, 8, 3371-3374.
19. Pinney, K. G.; Mejia, M. P.; Villalobos, V. M.; Rosenquist, B. E.; Pettit, G. R.; Verdier-Pinard, P.; Hamel, E. Bioorg. Med. Chem. 2000, 8, 2417-2425.
20. Pinney, K. G.; Jelinek, C.; Edvardsen, K.; Chaplin, D. J.; Pettit, G. R. In Anticancer Agents from Natural Products; Cragg, G. R.; Kingston, D. G. I., Newman, D. J., Eds.; CRC Press/Taylor & Francis: Boca Raton, FL, 2005; pp 23-46..
21. Ohsumi, K.; Hatanka, T.; Nakagawa, R.; Fukuda, Y.; Morinaga, Y.; Suga, Y.; Nihei, Y.; Ohishi, K.; Akiyama, Y.; Tsuji, T. Anti-Cancer Drug Des. 1999, 14, 539-548.
22. Demers, B.; Vrignaud, P.; Bissery, M J. Clin. Oncol. (2006 ASCO Ann. Meet. Proc., Part 1) 2006, 24, 18S13074 (abstract).
23. Hori, K; Saito, S. Br. J. Cancer 2003, 89, 1334-1344.
24. (a) Monk, K. A.; Siles, R.; Hadimani, M. B.; Mugabe, B. E.; Ackley, J. F.; Studerus, S. W.; Edvardsen, K.; Trawick, M. L.; Garner, C. M.; Rhodes, M. R.; Pettit, G. R.; Pinney, K. G. Bioorg. Med. Chem. 2006, 14, 3231-3244.
25. (b) Subsequent to the publication noted in ref 24a, an additional paper appeared later: Chang, J. Y.; Yang, M. F.; Chang, C. Y.; Kuo, C. C.; Liou, J. P. J. Med. Chem. 2006, 49, 6412-6415.
26. (a) Chaplin, D. J.; Garner, C. M.; Kane, R. R.; Pinney, K. G.; Prezioso, J. A.; Edvardsen, K. United States Patent US 6,919,324 B2, July 19 2005.
27. (b) Chaplin, D. J.; Garner, C. M.; Kane, R. R.; Pinney, K. G.; Prezioso, J. A.; Edvardsen, K. PCT Patent Publication WO 2003035008 A2, 2003.
28. Akerley, W. L.; Schabel, M.; Morrell, G.; Horvath, E.; Yu, M.; Johnsson, B.; Arbogast, K. J. Clin. Oncol. (2007 ASCO Ann. Meet. Proc., Part 1) 2007, 25, 18S, 14060 (abstract).
29. Patterson, D. M.; Ross, P.; Koetz, B.; Saleem, A.; Stratford, M.; Stirling, J.; Padhani, A.; Asselin, M.; Price, P.; Rustin, G. J. J. Clin. Oncol. (2007 ASCO Ann. Meet. Proc, Part 1) 2007, 25, 18S, 14146 (abstract).
30. Ohta, A.; Tonomura, Y.; Sawaki, J.; Sato, N.; Akiike, H.; Ikuta, M.; Shimazaki, M. Heterocycles 1991, 32, 965-973.
31. Monk, K.; Siles, R.; Pinney, K. G.; Garner, C. M. Tetrahedron Lett. 2003, 44, 3759-3761.
32. Gal'bershtam, M. A.; Budarina, Z. N. Z. Organ. Khim. 1969, 5, 953-956.
33. Simonsen, J. L.; Rau, M. G. J. Chem. Soc., Dalton Trans. 1917, 220, 236.
34. Crystallographic data for structure 13 (deposition number CCDC-654067) and structure 16 (deposition number CCDC-653756) reported in this paper have been deposited with the Cambridge Crystallographic Data Centre. Copies of the data can be obtained, free of charge, on application to the Director, CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: +44-(0)1223-336033 or e-mail: deposit@ccdc.cam.ac.uk).
35. Pettit, G. R.; Anderson, C. R.; Herald, D. L.; Jung, M. K.; Lee, D. J.; Hamel, E.; Pettit, R. K. J. Med. Chem. 2003, 46, 525-531.
36. Pettit, G. R.; Grealish, M. P.; Herald, D. L.; Boyd, M. R.; Hamel, E.; Pettit, R. K. J. Med. Chem. 2000, 43, 2731-2737.
37. Chaplin, D. J.; Edvardsen, K.; Pinney, K. G.; Prezioso, J. A.; Wood, M. PCT Patent Publication WO 2004078126 A2, 2004.
38. Portions of this work have appeared in the following dissertations: (a) Hadimani, M. B. Studies Toward the Discovery of New Classes of Privileged Molecules as Colchicine-Site Binding Ligands for Tubulin: Structure-Based Design, Synthesis, and Bioactivity of Small Ligands Targeted at Tumor Vasculature. Ph.D. Dissertation, Baylor University, Waco, TX, 2004.
39. (b) Siles, R. Design, Synthesis and Biological Evaluation of New Anti-Cancer Nitrogen-Containing Combretastatins and Novel Cysteine Protease Inhibitors for the Treatment of Chagas Disease. Ph.D. Dissertation, Baylor University, Waco, TX, 2005.
40. (c) Mugabe, B. E. Structure-activity Relationships and Thermodynamics of Combretastatin A-4 and A-1 Derivatives as Potential Inhibitors of Tubulin Polymerization. Ph.D. Dissertation, Baylor University, Waco, TX, 2005.
41. Sheldrick, G. M. SADABS; University of Göttingen: Göttingen, Germany, 1997.
42. Sheldrick, G. M. SHELXTL, 6.10 ed.; Bruker AXS, Inc: Madison, WI, 2000.
43. Hamel, E.; Lin, C. M. Biochemistry 1984, 23, 4173-4184.
44. Mosmann, T. J. Immunol. Methods 1983, 65, 55-63.
45. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paul, K.; Vestica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolf, A. J. Natl. Cancer Inst. 1991, 83, 757-766.
46. Pettit, G. R.; Meng, Y.; Stevenson, C. A.; Doubek, D. L.; Knight, J. C.; Cichacz, Z.; Pettit, R. K.; Chapuis, J.-C.; Schmidt, J. M. J. Nat. Prod. 2003, 66, 259-262.